Checkpoint inhibitor market

Posted by Shiva on August 6th, 2019

Market Overview:

The world checkpoint inhibitors market was worth ,566 million in 2018 and is expected to reach ,530 million by 2023, registering a CAGR of 20.1% from 2018 to 2023. Immune checkpoint inhibitor is a kind of drug used in immunotherapy. Although conventional chemotherapeutic drugs remain the first-line option for treatment of most cancer types, targeted immune therapies are rising as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system.

Market drivers and restraints:

The surge in the prevalence of cancer across geographies and rise in awareness of immune checkpoint inhibitors drive the growth of the world immune checkpoint inhibitors market. Moreover, technological advancements in screening procedure for cancer, increased healthcare expenditures, rise in government initiatives to alleviate cancer, an increase in public awareness are estimated to fuel the growth of the market. Nevertheless, the high cost associated with research activities is expected to restrain market growth.

To know more, click on the link below:

Report segmented as:

By type:

  •         CTLA-4 inhibitor
  •         PD-1 inhibitor
  •         PD-L1 inhibitor
  •         others

By application:

  •         lung cancer
  •         bladder cancer
  •         melanoma
  •         Hodgkin lymphoma
  •         others

Geographical analysis:

Based on geography, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA). Asia-Pacific presents lucrative opportunities for the major players operating in the immune checkpoint inhibitors market, due to large population base, growth in awareness about advanced immune therapy, the surge in the incidence of cancer, and improvement of healthcare infrastructure. China, Japan, and India have a high prevalence of cancer, which is estimated to drive the demand for immune checkpoint inhibitors in the coming future.

Important market players:

The major players operating in the global checkpoint inhibitor market are AstraZeneca PLC., Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.

View a sample and decide @

The Scope of the report:

This report offers the current product and services market evaluation and the future estimation of the market. It helps us understand the market better through size anticipation and CAGR calculation to estimate the next market. It has a broader segmentation for better understanding of the enterprising of the market at a low level by segregating the market into smaller sectors.

Apart from the syndicated report, our in-house team has expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.

About Us:

Market Data Forecast is a firm working in the areas of market research, business intelligence, and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.

For more information:

Abhishek Shukla

Sales Manager at Market Data Forecast


Tel: +1-888-702-9626


Like it? Share it!


About the Author

Joined: June 11th, 2019
Articles Posted: 88

More by this author